T-cell agonists in cancer immunotherapy
Cancer cells can evade immune surveillance in the body. However, immune checkpoint inhibitors can interrupt this evasion and enhance the antitumor activity of T cells. Other mechanisms for promoting antitumor T-cell function are the targeting of costimulatory molecules expressed on the surface of T...
Saved in:
| Main Authors: | Gennaro Ciliberto, Aung Naing, Joud Hajjar, Cara L Haymaker, Yeonjoo Choi, Yaoyao Shi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/2/e000966.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Strategies for improving the management of immune-related adverse events
by: James L Gulley, et al.
Published: (2020-10-01) -
Urease-powered nanomotor containing STING agonist for bladder cancer immunotherapy
by: Hyunsik Choi, et al.
Published: (2024-11-01) -
Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy
by: Riyue Bao, et al.
Published: (2022-02-01) -
Exploring the synergy between tumor microenvironment modulation and STING agonists in cancer immunotherapy
by: Xiaoyan Qi, et al.
Published: (2024-12-01) -
T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy
by: Linghua Wang, et al.
Published: (2023-08-01)